Yükleniyor... / Loading...
This registry study aims to examine broad genomic testing and the medical decisions made as a result in cancer patients. It was designed for cancer patients aged 18 and over for whom genomic profiling was considered appropriate based on medical need. The study was conducted as a trial without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: This registry will include cancer patients for which broad genomic profiling is indicated as assessed by the medical need and as deemed appropriate by the physician, for example * cancer with high mutational load and suspicion of regular or frequent formation of neoantigens * skin, lung, stomach, esophagus, colorectum, bladder, uterus, cervix, liver, head and neck, kidney, breast * lymphoma B-cell * any other neoplastic disease where molecular targeting is performed but treatment fails * cancer of unknown primary origin (CUP) * planned or already carried out comprehensive genomic testing as of Jan 1, 2016 note: this registry will not initially register patients who are tested for only 1-5 mutations by conventional means, but patients undergoing genomic profiling based on NGS) * a patient´s signed informed consent * Patients ≥ 18 years of age Exclusion Criteria: * Due to the non-interventional design of the registry there are no specific exclusion criteria.